Net debt/EBITDA společnosti ProMIS Neurosciences
Jaká je hodnota metriky Net debt/EBITDA společnosti ProMIS Neurosciences?
Hodnota metriky Net debt/EBITDA společnosti ProMIS Neurosciences, Inc. je 3.64
Jaká je definice metriky Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA společností v sektoru Health Care sektor na TSX ve srovnání se společností ProMIS Neurosciences
Čemu se věnuje společnost ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Firmy s metrikou net debt/ebitda podobnou společnosti ProMIS Neurosciences
- Hodnota metriky Net debt/EBITDA společnosti Global Atomic je 3.63
- Hodnota metriky Net debt/EBITDA společnosti Southern Copper je 3.64
- Hodnota metriky Net debt/EBITDA společnosti Vedan International () je 3.64
- Hodnota metriky Net debt/EBITDA společnosti Extendicare je 3.64
- Hodnota metriky Net debt/EBITDA společnosti Xenetic Biosciences Inc je 3.64
- Hodnota metriky Net debt/EBITDA společnosti CGI je 3.64
- Hodnota metriky Net debt/EBITDA společnosti ProMIS Neurosciences je 3.64
- Hodnota metriky Net debt/EBITDA společnosti Branding China je 3.64
- Hodnota metriky Net debt/EBITDA společnosti Marathon Petroleum Corp je 3.64
- Hodnota metriky Net debt/EBITDA společnosti e Guillin S.A je 3.65
- Hodnota metriky Net debt/EBITDA společnosti New Dimension Resources je 3.65
- Hodnota metriky Net debt/EBITDA společnosti Huanxi Media je 3.65
- Hodnota metriky Net debt/EBITDA společnosti Indiana Resources je 3.65